December 27, 2024 11:59 AM EST

FDA approves subcutaneous version of Bristol Myers' Opdivo

Kyle LaHucik

Senior Reporter

A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been approved in a subcutaneous form …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves subcutaneous version of Bristol Myers' Opdivo

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Exclusive: Florida cancer biotech raises $100M Series A

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Exclusive: Florida cancer biotech raises $100M Series A

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market